Diurnal Variations of Endogenous Steroids in the Follicular Phase of the Menstrual Cycle

Anna Tiihonen Möller1*, Torbjörn Bäckström2, Hans Peter Söndergaard3, Mark M Kushnir4,5, Jonas Bergquist1,4 and Lotti Helström1

1 Department of Clinical Science and Education, Karolinska Institutet, Department of Obstetrics and Gynecology, Stockholm South Hospital, Stockholm, Sweden
2 Department of Clinical Science, Obstetrics and Gynecology, Umeå University, Umeå, Sweden
3 Department of Chemistry - Biomedical Centre, Analytical Chemistry and SciLifeLab, Uppsala University, Uppsala, Sweden
4 Department of Pathology, University of Utah, Salt Lake City, USA
5 ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, USA

Abstract

Rationale: The diurnal variations of cortisol and of other upstream glucocorticoid steroids have been well described. However, diurnal variations of other steroids in the steroid synthesis pathways have not been fully addressed in the literature.

Objective: To explore possible diurnal variations of several endogenous steroids.

Methods: Blood samples were taken every four hours during 24 hours in 10 healthy drug naïve pre-menopausal women in the follicular phase of the menstrual cycle. Using the LC-MS/MS technique, serum was analyzed for concentrations of glucocorticoids (cortisol, cortisone, 11-deoxycortisol), androgens (androstenedione, testosterone, DHEA), pregnenes (pregnenolone, 17OH-pregnenolone), progestins (progesterone, 17OH-progesterone), and estrogens (estrone, estradiol). The concentration of the anesthetic steroid allopregnanolone was analyzed using the radioimmunoassay (RIA) technique. The blood samples were divided into six time intervals: 02:01-06:00, 06:01-10:00, 10:01-14:00, 14:01-18:00, 18:01-22:00, and 22:01-02:00. Each steroid was tested for possible diurnal variation using repeated measures ANOVA for within-subject variation.

Results: All steroids except the estrogens exhibited a significant diurnal variation (p<0.05). Apart from allopregnanolone, all the steroids peaked in concentration at 08:00 (e.g., just after awakening). Allopregnanolone had a flatter curve, its highest concentrations occurring throughout the day and its peak concentrations at about 12:00.

Conclusions: The present study suggests that when assessing concentrations of steroids in the glucocorticoid group and those in the pregnene, androgen, and progestine groups, as well as allopregnanolone, it might be necessary to accounted for a diurnal variation. However, a possible interaction between menstrual-cycle phase and the hypothalamus-pituitary-adrenal (HPA) axis and the diurnal variations of the steroids should be confirmed by future studies.

Keywords: Diurnal variations; Circadian rhythm; Endogenous steroids; Allopregnanolone; Menstrual cycle; Women

Introduction

Many studies have been conducted assessing biological changes in patients with both somatic and psychiatric conditions. Most studies of posttraumatic stress disorder (PTSD) have focused on the primary stress pathway: the hypothalamus-pituitary-adrenal axis (HPA), which is activated during acute stress. The hypothalamic secretes corticotropin-releasing factor (CRF) which stimulates the pituitary to release adrenocorticotropic hormone (ACTH), resulting in the production of glucocorticoids and other steroids in the adrenal cortex. It is known that the secretion of cortisol is associated with the natural circadian rhythm, and the assessment of cortisol concentrations should be adjusted for the diurnal variation, with peak values in the morning just after awakening. As cortisol is one of the end products of the glucocorticoid biosynthesis pathway, it can be assumed that the biosynthesis of glucocorticoids upstream and other steroids (Figure 1) also are affected by diurnal variations.

Dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) are synthesized from cholesterol, via pregnenolone (sulfate) and 17-hydroxyprogrenolone, almost exclusively by the adrenals, only ± 10% of plasma DHEA is derived from the gonads [2]. DHEAS is quantitatively the major steroid hormone secreted by the adrenals, and its plasma concentration in young adults is 10 to 20 times the cortisol concentration. DHEAS has a low metabolic-clearance rate, and as a consequence of this, DHEAS is practically constant during the day and night [3]. However, the concentration of DHEA is 500 to 1,000 times lower than that of DHEAS, and studies have shown that DHEA levels show both pulsatile and nyctohemeral variations, in parallel with cortisol and ACTH pulses [4]. DHEA is also a precursor of testosterone and estrone. One could therefore surmise that the concentrations of these steroids also have diurnal variations.

Alterations in the neuroactive steroid allopregnanolone in PTSD patients have been suggested. Allopregnanolone, another stress steroid, is anesthetic and anxiolytic. It is converted from progesterone by the
rate-limiting enzyme 5α-reductase and has been found at decreased concentrations in cerebrospinal fluid and serum in both patients with PTSD and those with depression [5,6]. It has been determined that allopregnanolone does not manifest a diurnal variation during the luteal phase of the menstrual cycle [7], but there are no reports supporting its diurnal variation during the follicular phase.

Recent studies suggest that alterations occur in steroid concentrations soon after a traumatic event, suggesting that acute biological responses may serve as risk or resilience factors for the development of PTSD. To assess whether an acute response to a trauma is associated with the steroid concentrations, one needs to know whether it is necessary to account for a diurnal variation of that particular steroid.

In this study, concentrations of the steroids were measured using mainly LC-MS/MS techniques, recognized as the best available methodology for the analysis of endogenous steroids [8,9]. Six classes of steroids were measured: anesthetic steroid (allopregnanolone), glucocorticoids (cortisol, cortisone, 11-deoxycortisol), androgens (androstenedione, testosterone, DHEA), pregnenes (pregnenolone, 17OH-pregnenolone), progestins (progesterone, 17OH-progesterone) and estrogens (estrone, estradiol). Concentrations of the steroids were then examined to determine their diurnal variation and their correlation to each other.

**Methods**

**Participants**

Ten non-traumatized women were recruited through advertisement. Before entering the study, all participants received written and oral information about the study and signed a written-consent form. Everyone received a medical screening consisting of a physical examination and a test of thyroid and liver function. The study was approved by the local medical ethics committee in Stockholm (2011/851-31/3).

**Inclusion criteria:** Women between 18 and 40 years old, who were not taking any hormonal contraceptives or daily medications, and who were physically and mentally healthy were included. Participants had to experience regular menstruations, and all blood sampling was conducted during the follicular phase of their menstrual cycles (days 6-12). Participants had to score low on the Beck Depression Inventory (BDI), the Stanford Acute Stress Reaction Questionnaire (SASRQ), and the Structured Clinical Interview for DSM-IV (SCID-I) interview. These scales are clarified later in this article.

**Exclusion criteria:** Potential participants were excluded if they had a history of psychosis, major or bipolar depression, alcohol or substance abuse, neurological disease, endocrine disease, polycystic ovarian syndrome (PCOS), premenstrual dysphoric disorder (PMDD) or if they were pregnant. Further, women were excluded if they were smokers or were taking any daily medications, such as antidepressants, anxiolytics, and sedative drugs. Potential participants were also excluded from the study if they reported having taken any benzodiazepines in the three months before the challenge (including any occasional medication) or having consumed alcohol within 72 hours before the blood sampling.

**Psychometrics used during inclusion:** The Beck Depression Inventory [10] is a 21-item inventory measuring depressive mood and vegetative symptoms of depression. Cut-off points for the sum scores were 0-9 (no depression), 10-16 (mild depression), 17-29 (moderate depression), and ≥ 30 (severe depression). Participants were allowed to score a maximum of nine points.

The Stanford Acute Stress Reaction Questionnaire, SASRQ [11] is mainly used to diagnose ASD, but in this study it was used as a total score for measuring PTSD symptoms. To be included, participants had to have low scores (<10 out of a possible 150 points). The PTSD Module of the Structured Clinical Interview for DSM-IV (SCID-I) [12] was also used to establish the absence of posttraumatic stress symptoms. Participants had to score zero out of a possible six points.

**Procedures**

The study was conducted in a hospital setting, in a room at the Emergency Clinic for Raped Women at Stockholm South General Hospital, Sweden. An intravenous catheter was inserted in the forearum, at a minimum of one hour before the first blood draw. Blood samples were drawn every fourth hour for 24 hours during the follicular phase.

![Image: Steroid synthesis pathways](image-url)
The blood was collected from the antecubital veins of the women's sleep. Participants slept in an ordinary bed in a quiet research room and according to their usual diurnal cycles. The blood draws were performed six times, once during each of the intervals 02:01-06:00, 06:01-10:00, 10:01-14:00, 14:01-18:00, 18:01-22:00, and 22:01-02:00. Mean and standard deviation for each time interval and steroid were calculated. The blood samples were tested for each steroid’s diurnal variation using repeated measures ANOVA for within-subject variation. Spearman correlation coefficient was calculated to assess the correlation between concentrations of the steroids. Results were considered significant when the p-value was less than 0.05. All statistical analyses were conducted using the statistical software version SPSS 22.0.

Results

Concentrations of steroids at each time interval

Serum concentrations for each steroid and time interval are listed in Table 1. Concentrations of progesterone in the follicular phase were low, and most samples were below the sensitivity of the assay. Therefore, progesterone was excluded from further analyses.

Diurnal variations

All steroids, with the exception of estrone and estradiol, had a diurnal variation with significant within-subject variation (see Table 1). Apart from allopregnanolone, all steroids peaked in concentration during time interval 2 (i.e., around 08.00, just after awakening). For cortisol, cortisone, pregnenolone, 17OH-pregnenolone, DHEA, 17OH-progesterone, and androstenedione, the mean concentration at time interval 2 was significantly higher than the mean concentrations in all the other time intervals.

Allopregnanolone exhibited flatter curve then the other steroids did, its highest concentrations occurring in time intervals 2, 3, and 4 (i.e., between 06:00 and 18:00). The highest serum concentration of allopregnanolone was seen during time interval 3. Serum concentration did, its highest concentrations occurring in time intervals 2, 3, and 4.
The major findings of the present study were that all measured steroids, with the exception of estrogens, showed a diurnal variation in the follicular phase of the menstrual cycle. For all measured steroids, with the exception of allopregnanolone, peak concentrations were observed around 08:00. Allopregnanolone peaked throughout the day, its highest concentrations occurring around 12:00. Further, we saw correlations between a majority of the steroids.

The finding that almost all steroids have a natural circadian rhythm is interesting and further demonstrates the importance of adjusting for this in studies examining differences in serum concentrations of steroids in certain patient groups when the subjects are pre-menopausal women in the follicular phase of their menstrual cycles. The finding of a diurnal variation in allopregnanolone is interesting because no variation was seen in the luteal phase of the menstrual cycle in patients with PMDD or in controls [7]. This suggests that allopregnanolone is secreted from the adrenals in the follicular phase with a rhythm similar to that of the gluco corticoids, but on a flatter curve. The somewhat different slope on the curve might be caused by the longer biosynthesis pathway to glucocorticoids, but on a flatter curve. The somewhat different slope on the curve might be caused by the longer biosynthesis pathway to glucocorticoids, but on a flatter curve.

As seen in Table 2, apart from the estrogens, which being correlated only with each other, high correlations occurred between almost all the steroids.

**Discussion**

The present study is unique, as it is the first to explore the relationship between concentrations of steroids in the pathway of steroid biosynthesis in reproductive-age women during the follicular phase of the menstrual cycle.

Table 1: Concentrations of steroids (ng/mL) in serum at each time interval. Data presented as mean ± SEM.

<table>
<thead>
<tr>
<th>T1</th>
<th>T2</th>
<th>T3</th>
<th>T4</th>
<th>T5</th>
<th>T6</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>02:01-06:00</td>
<td>06:01-10:00</td>
<td>10:01-14:00</td>
<td>14:01-18:00</td>
<td>18:01-22:00</td>
<td>22:01-02:00</td>
<td></td>
</tr>
<tr>
<td>Allopregnanolone</td>
<td>0.102 ± 0.009</td>
<td>0.125 ± 0.009</td>
<td>0.141 ± 0.014</td>
<td>0.125 ± 0.013</td>
<td>0.118 ± 0.013</td>
<td>0.103 ± 0.012</td>
</tr>
<tr>
<td>Cortisol</td>
<td>67.50 ± 14.07</td>
<td>146.20 ± 11.67</td>
<td>67.90 ± 6.16</td>
<td>76.67 ± 7.29</td>
<td>35.00 ± 6.68</td>
<td>25.40 ± 4.81</td>
</tr>
<tr>
<td>Cortisone</td>
<td>15.40 ± 1.81</td>
<td>27.10 ± 1.34</td>
<td>20.10 ± 1.20</td>
<td>20.70 ± 1.19</td>
<td>13.20 ± 1.40</td>
<td>9.70 ± 0.97</td>
</tr>
<tr>
<td>11-DC</td>
<td>0.110 ± 0.051</td>
<td>0.215 ± 0.062</td>
<td>0.013 ± 0.005</td>
<td>0.045 ± 0.031</td>
<td>0.002 ± 0.002</td>
<td>0.002 ± 0.002</td>
</tr>
<tr>
<td>Pregnenolone</td>
<td>1.030 ± 0.118</td>
<td>1.660 ± 0.119</td>
<td>1.060 ± 0.065</td>
<td>1.150 ± 0.089</td>
<td>0.940 ± 0.060</td>
<td>0.780 ± 0.051</td>
</tr>
<tr>
<td>17OH-Preg</td>
<td>1.160 ± 0.656</td>
<td>3.850 ± 0.732</td>
<td>0.960 ± 0.158</td>
<td>1.260 ± 0.445</td>
<td>0.370 ± 0.167</td>
<td>0.180 ± 0.076</td>
</tr>
<tr>
<td>DHEA</td>
<td>3.47 ± 0.53</td>
<td>5.67 ± 0.55</td>
<td>3.28 ± 0.35</td>
<td>3.46 ± 0.40</td>
<td>2.56 ± 0.28</td>
<td>2.08 ± 0.17</td>
</tr>
<tr>
<td>17OH-Prog</td>
<td>0.181 ± 0.03</td>
<td>0.302 ± 0.04</td>
<td>0.146 ± 0.007</td>
<td>0.149 ± 0.020</td>
<td>0.121 ± 0.010</td>
<td>0.114 ± 0.019</td>
</tr>
<tr>
<td>Testosterone</td>
<td>0.197</td>
<td>0.230 ± 0.018</td>
<td>0.187 ± 0.014</td>
<td>0.195 ± 0.021</td>
<td>0.178 ± 0.008</td>
<td>0.185 ± 0.019</td>
</tr>
<tr>
<td>Androstenedione</td>
<td>0.039 ± 0.119</td>
<td>1.330 ± 0.164</td>
<td>0.866 ± 0.094</td>
<td>0.901 ± 0.125</td>
<td>0.700 ± 0.070</td>
<td>0.700 ± 0.085</td>
</tr>
<tr>
<td>Estrone</td>
<td>0.037 ± 0.003</td>
<td>0.037 ± 0.004</td>
<td>0.033 ± 0.003</td>
<td>0.039 ± 0.005</td>
<td>0.034 ± 0.003</td>
<td>0.037 ± 0.005</td>
</tr>
<tr>
<td>Estradiol</td>
<td>0.053 ± 0.010</td>
<td>0.054 ± 0.009</td>
<td>0.068 ± 0.010</td>
<td>0.048 ± 0.010</td>
<td>0.045 ± 0.008</td>
<td>0.049 ± 0.008</td>
</tr>
</tbody>
</table>

Note: Data for progesterone are not listed, as concentrations in follicular phase were below LOQ of the assay. *P-value regarding within-subject variation for each steroid using repeated measures ANOVA.

<table>
<thead>
<tr>
<th>T1</th>
<th>T2</th>
<th>T3</th>
<th>T4</th>
<th>T5</th>
<th>T6</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Allo</td>
<td>0.108</td>
<td>0.268**</td>
<td>0.409**</td>
<td>0.187</td>
<td>0.383**</td>
<td>0.051</td>
</tr>
<tr>
<td>2. Cortisol</td>
<td>1</td>
<td>0.902**</td>
<td>0.650**</td>
<td>0.850**</td>
<td>0.652**</td>
<td>0.574**</td>
</tr>
<tr>
<td>3. Cortisone</td>
<td>1</td>
<td>0.648**</td>
<td>0.734**</td>
<td>0.590**</td>
<td>0.524**</td>
<td>0.056</td>
</tr>
<tr>
<td>4. Pregnenolone</td>
<td>1</td>
<td>0.711**</td>
<td>0.744**</td>
<td>0.661**</td>
<td>0.423**</td>
<td>0.674**</td>
</tr>
<tr>
<td>5. 17OH-Preg</td>
<td>1</td>
<td>0.857**</td>
<td>0.709**</td>
<td>0.296**</td>
<td>0.591**</td>
<td>0.191</td>
</tr>
<tr>
<td>6. DHEA</td>
<td>1</td>
<td>0.622**</td>
<td>0.527**</td>
<td>0.687**</td>
<td>0.081</td>
<td>0.026</td>
</tr>
<tr>
<td>7. 17OH-Prog</td>
<td>1</td>
<td>0.545**</td>
<td>0.814**</td>
<td>0.205</td>
<td>0.095</td>
<td></td>
</tr>
<tr>
<td>8. Testosterone</td>
<td>1</td>
<td>0.792**</td>
<td>0.092</td>
<td>0.004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. A4</td>
<td>1</td>
<td>0.106</td>
<td>0.046</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Estrone</td>
<td>1</td>
<td>0.485**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Estradiol</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p<0.05; **p<0.01; ***p<0.001; A4: Androstenedione

Table 2: Relationships between serum steroid concentrations. Correlation coefficients and the corresponding p-values are given.

Bivariate correlations

As seen in Table 2, apart from the estrogens, which being correlated only with each other, high correlations occurred between almost all the steroids.
Figure 2: Serum concentrations of allopregnanolone, cortisol, and cortisone during 24 hours presented as mean ± SEM.

Figure 3: Serum concentrations of 17OH-progesterone, 17OH-pregnenolone and pregnenolone during 24 hours presented as mean ± SEM.

diurnal secretion of cortisol in the luteal phase could be influenced by concentrations of allopregnanolone. Further, they suggested that the timing of blood sampling and individual levels of allopregnanolone could explain the discrepancies in studies examining the HPA axis in PMDD patients. One could assume also that when interpreting the HPA axis in PTSD patients, allopregnanolone concentrations should be considered. Not adjusting for female patients in luteal phase of the menstrual cycle (i.e., when allopregnanolone concentrations are known to be high [20]) could potentially blunt the results. In a recent study, Inslicht et al. [21] discussed difficulties in interpreting neurosteroid responses in pre-menopausal women, suggesting that the reproductive hormones may be involved in modulating the HPA axis.

In the present study all participants were in the follicular phase of the menstrual cycle, and no correlation was seen between allopregnanolone and cortisol ($r=0.108, p=0.429$). However, correlations were found between allopregnanolone, pregnenolone, and DHEA and between all steroids (except the estrogens) and androstenedione. Estrone and estradiol correlated with each other but not with any of the other steroids.

Conclusions

In sum, the present study suggests that just as there is for the glucocorticoids, there is also a natural circadian rhythm to allopregnanolone, the pregnenes, androgens, and progestins in the follicular phase of the menstrual cycle. However, a possible interaction between menstrual-cycle phase and the HPA axis, as well as the diurnal variations of the steroids, should be strengthened with future studies.
Diurnal variations

Figure 4: Serum concentrations of androstenedione, DHEA, and testosterone during 24 hours presented as mean ± SEM.

Figure 5: Serum concentrations of estradiol and estrone during 24 hours presented as mean ± SEM.

Acknowledgements

This study was funded by grants from the Swedish Research Council (Project numbers: 90418601, 621-2011-4423), ALF funding from the Stockholm Council County, the Spearhead Grant, and ALF funding from the Västerbotten County Council, as well as a grant from the Swedish insurance company Folksam, aimed for rape victims. The authors thank the ARUP Institute for Clinical and Experimental Pathology (Salt Lake City, USA) for supporting this project, and Elisabeth Zingmark for conducting the allopregnanolone assays.

References


